Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 Aprile 2024 - 4:01PM
Business Wire
Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global
biopharmaceutical company tackling some of the greatest unmet needs
in oncology by developing differentiated and novel therapeutic
candidates, today announced that updated data from the Phase 2
TRUST-I clinical study (NCT04395677) evaluating taletrectinib in
patients in China with ROS1-positive non-small cell lung cancer
(NSCLC) will be reported in an oral presentation at the 2024
American Society of Clinical Oncology (ASCO) Annual Meeting taking
place May 31-June 4, 2024 in Chicago, Illinois.
Presentation Overview:
Title: Efficacy and safety of taletrectinib in patients
with advanced or metastatic ROS1+ non-small cell lung cancer: The
phase 2 TRUST-I study Presenter: Wei Li, M.D., Department of
Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer
Institute, Tongji University School of Medicine Date:
Saturday, June 1, 2024 Session Time: 4:30-6:00 p.m.
CT/5:30-7:00 p.m. ET Session: Lung Cancer — Non-Small Cell
Metastatic Abstract: 8520
The materials will be made available on the Publications section
of nuvationbio.com the morning of the presentation.
About Taletrectinib
Taletrectinib is an oral, potent, central nervous system-active,
selective, next-generation ROS1 inhibitor specifically designed for
the potential treatment of patients with ROS1-positive NSCLC.
Taletrectinib is being evaluated for the treatment of patients
with ROS1-positive NSCLC in two Phase 2 single-arm pivotal studies:
TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a
global study.
Taletrectinib has been granted Breakthrough Therapy Designations
by both the U.S. Food and Drug Administration (FDA) and China’s
National Medical Products Administration (NMPA) for the treatment
of patients with advanced or metastatic ROS1-positive NSCLC. Based
on results of the TRUST-I clinical study, China’s NMPA has accepted
and granted Priority Review Designations to New Drug Applications
for taletrectinib for the treatment of adult patients with locally
advanced or metastatic ROS1-positive NSCLC who either have or have
not previously been treated with ROS1 tyrosine kinase inhibitors
(TKIs).
About Nuvation Bio
Nuvation Bio is a late-stage, global biopharmaceutical company
tackling some of the greatest unmet needs in oncology by developing
differentiated and novel therapeutic candidates. Nuvation Bio’s
portfolio of development candidates includes taletrectinib (ROS1),
safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation
Bio was founded in 2018 by biopharma industry veteran David Hung,
M.D., who previously founded Medivation, Inc., which brought to
patients one of the world’s leading prostate cancer medicines.
Nuvation Bio has offices in New York, San Francisco, and Shanghai.
For more information, please visit www.nuvationbio.com and
https://www.linkedin.com/company/nuvationbio/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424848536/en/
Nuvation Bio Investor: ir@nuvationbio.com
Nuvation Bio Media: nuvation@argotpartners.com
Grafico Azioni Panacea Acquisition (NYSE:NUVB)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Panacea Acquisition (NYSE:NUVB)
Storico
Da Gen 2024 a Gen 2025
